Regenxbio Inc.

Most Recent

  • uploads///medicine _
    Company & Industry Overviews

    Why Arrowhead Pharmaceuticals Stock Rose Over 10% Yesterday

    On December 12, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.19, an ~11.53% rise from its previous day’s close of $13.62.

    By Daniel Collins
  • uploads///Arrowhead
    Company & Industry Overviews

    Arrowhead Pharmaceuticals Stock Has Risen ~252% Year-to-Date

    On November 21, Arrowhead Pharmaceuticals (ARWR) stock closed at $12.95, a ~5.28% rise from its previous day’s close of $12.30.

    By Daniel Collins
  • uploads///EDIT
    Company & Industry Overviews

    Editas Stock: Analysts’ Recommendations

    In November, among the ten analysts covering Editas Medicine (EDIT), six analysts recommended a “buy,” while four recommended a “hold.”

    By Kenneth Smith
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///regenxbio ana reco
    Company & Industry Overviews

    Analyzing Regenxbio’s Valuation Metrics

    Regenxbio (RGNX) generated revenues of $40.03 million in the second quarter compared to $6.56 million in Q2 2017.

    By Kenneth Smith
  • uploads///Regenxbio clinical pipeline
    Company & Industry Overviews

    Are You Following Regenxbio in 2018?

    Regenxbio (RGNX), a clinical stage biotechnology company, is exploring the curative potential of gene therapy.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    How Analysts Rate Editas Medicine and Peers in August

    Editas Medicine (EDIT) is a research-stage genome editing company. Five of the total nine analysts covering the company in August have given the stock a “buy” rating.

    By Kenneth Smith
  • uploads///business __
    Healthcare

    Netflix to Join S&P 100, Twitter to Join S&P 500, REGENEXBIO to Join S&P SmallCap 600

    Netflix Inc. (NFLX), Twitter Inc. (TWTR), and REGENXBIO Inc. (RGNX) are up in pre-market trading on news that they will be added to certain S&P Dow Jones Indices. Here’s what you need to know.

    By Joey Solitro
  • uploads///RGNX
    Company & Industry Overviews

    How Regenxbio’s Cash Flows and Valuation Metrics Moved

    Regenxbio (RGNX) spent $57.9 million in operating activities in fiscal 2017 compared to $48.5 million in fiscal 2016.

    By Kenneth Smith
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.